Subsequent Events

9 Months Ended

Apr. 30, 2014

Subsequent Events

On May 15, 2014, the Company entered into an agreement and subsequently received funding from an investor in the amount of $300,000 for use by the Company for any purpose, including the research, development, marketing and commercialization of the Company's opioid overdose reversal treatment. In exchange for this funding, the Company agreed to provide the investor with a 1.5% interest in the product and pay the investor 1.5% of the net profit generated from the product used for this treatment after the deduction of all expenses incurred by and payments made by the Company in connection with the product, including but not limited to an allocation of Company overhead. If the product is not introduced to the market and not approved for marketing within 24 months of the date of investment, the investor will have a sixty day option to receive 3,750,000 shares of common stock in lieu of the 1.5% interest in the product.